Answers are grounded in this paper and cite their sources.
Vancomycin-resistant Staphylococcus aureus (VRSA) endocarditis is a rare, life-threatening infection typically linked to healthcare exposure or immunocompromised hosts. We report the first case of community-acquired native mitral valve endocarditis caused by VRSA in a previously healthy 20-year-old woman without traditional risk factors, complicated by cerebral embolization and necrotizing pneumonia. The patient presented with acute-onset fever (41°C), hemorrhagic conjunctivitis, periorbital edema, and hypoxemia progressing to respiratory failure. Initial empiric therapy with meropenem and vancomycin failed; blood cultures confirming methicillin-resistant VRSA (vancomycin minimum inhibitory concentrations [MICs] >16 µg/mL) susceptible to linezolid and gentamicin. Echocardiography revealed a 1.2 cm mitral valve vegetation, and brain MRI revealed embolic infarcts in the midbrain and parietotemporal regions. A 4-week regimen of linezolid (600 mg q12h) and gentamicin (5 mg/kg/day) achieved microbiological clearance and clinical stabilization without surgical intervention. Residual right hemiparesis (MRC grade 4/5) improved with neurorehabilitation, and 3-month follow-up confirmed sustained recovery. This case highlights VRSA’s emergence as a community pathogen and exposes critical gaps in empiric therapy guidelines reliant on vancomycin. Urgent integration of molecular resistance profiling and updated treatment algorithms are essential to counter this escalating antimicrobial threat.
No takes yet. Share an insight, caveat, or question.
Taziki et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: